QQQ   352.58 (+1.08%)
AAPL   179.92 (+1.18%)
MSFT   324.99 (+0.50%)
META   264.97 (+0.52%)
GOOGL   122.14 (-0.29%)
AMZN   123.99 (+2.28%)
TSLA   232.81 (+3.67%)
NVDA   386.48 (+3.13%)
NIO   7.66 (-1.29%)
BABA   86.44 (+1.36%)
AMD   120.89 (+2.60%)
T   16.01 (-0.56%)
F   13.64 (+0.37%)
MU   65.03 (-3.03%)
CGC   0.70 (-2.78%)
GE   106.80 (+0.68%)
DIS   92.45 (-0.08%)
AMC   4.67 (-1.27%)
PFE   39.04 (+0.39%)
PYPL   64.24 (+0.31%)
NFLX   405.59 (+1.46%)
QQQ   352.58 (+1.08%)
AAPL   179.92 (+1.18%)
MSFT   324.99 (+0.50%)
META   264.97 (+0.52%)
GOOGL   122.14 (-0.29%)
AMZN   123.99 (+2.28%)
TSLA   232.81 (+3.67%)
NVDA   386.48 (+3.13%)
NIO   7.66 (-1.29%)
BABA   86.44 (+1.36%)
AMD   120.89 (+2.60%)
T   16.01 (-0.56%)
F   13.64 (+0.37%)
MU   65.03 (-3.03%)
CGC   0.70 (-2.78%)
GE   106.80 (+0.68%)
DIS   92.45 (-0.08%)
AMC   4.67 (-1.27%)
PFE   39.04 (+0.39%)
PYPL   64.24 (+0.31%)
NFLX   405.59 (+1.46%)
QQQ   352.58 (+1.08%)
AAPL   179.92 (+1.18%)
MSFT   324.99 (+0.50%)
META   264.97 (+0.52%)
GOOGL   122.14 (-0.29%)
AMZN   123.99 (+2.28%)
TSLA   232.81 (+3.67%)
NVDA   386.48 (+3.13%)
NIO   7.66 (-1.29%)
BABA   86.44 (+1.36%)
AMD   120.89 (+2.60%)
T   16.01 (-0.56%)
F   13.64 (+0.37%)
MU   65.03 (-3.03%)
CGC   0.70 (-2.78%)
GE   106.80 (+0.68%)
DIS   92.45 (-0.08%)
AMC   4.67 (-1.27%)
PFE   39.04 (+0.39%)
PYPL   64.24 (+0.31%)
NFLX   405.59 (+1.46%)
QQQ   352.58 (+1.08%)
AAPL   179.92 (+1.18%)
MSFT   324.99 (+0.50%)
META   264.97 (+0.52%)
GOOGL   122.14 (-0.29%)
AMZN   123.99 (+2.28%)
TSLA   232.81 (+3.67%)
NVDA   386.48 (+3.13%)
NIO   7.66 (-1.29%)
BABA   86.44 (+1.36%)
AMD   120.89 (+2.60%)
T   16.01 (-0.56%)
F   13.64 (+0.37%)
MU   65.03 (-3.03%)
CGC   0.70 (-2.78%)
GE   106.80 (+0.68%)
DIS   92.45 (-0.08%)
AMC   4.67 (-1.27%)
PFE   39.04 (+0.39%)
PYPL   64.24 (+0.31%)
NFLX   405.59 (+1.46%)
NASDAQ:TMDX

TransMedics Group (TMDX) Competitors

$79.72
+0.38 (+0.48%)
(As of 02:34 PM ET)
Compare
Today's Range
$77.10
$80.35
50-Day Range
$66.23
$88.73
52-Week Range
$24.01
$90.15
Volume
747,204 shs
Average Volume
534,990 shs
Market Capitalization
$2.59 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$72.29

TMDX vs. LIVN, ITGR, INMD, CNMD, OM, BLFS, MASI, BBIO, RVNC, and BEAM

Should you be buying TransMedics Group stock or one of its competitors? The main competitors of TransMedics Group include LivaNova (LIVN), Integer (ITGR), InMode (INMD), CONMED (CNMD), Outset Medical (OM), BioLife Solutions (BLFS), Masimo (MASI), BridgeBio Pharma (BBIO), Revance Therapeutics (RVNC), and Beam Therapeutics (BEAM). These companies are all part of the "medical" sector.

TransMedics Group vs.

TransMedics Group (NASDAQ:TMDX) and LivaNova (NASDAQ:LIVN) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, media sentiment, dividends, profitability, valuation and risk.

TransMedics Group has higher earnings, but lower revenue than LivaNova. TransMedics Group is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TransMedics Group$93.46 million27.49-$36.23 million-$0.95-83.07
LivaNova$1.02 billion2.49-$86.25 million-$1.54-30.67

LivaNova received 294 more outperform votes than TransMedics Group when rated by MarketBeat users. Likewise, 69.57% of users gave LivaNova an outperform vote while only 53.24% of users gave TransMedics Group an outperform vote.

CompanyUnderperformOutperform
TransMedics GroupOutperform Votes
74
53.24%
Underperform Votes
65
46.76%
LivaNovaOutperform Votes
368
69.57%
Underperform Votes
161
30.43%

TransMedics Group has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.

TransMedics Group presently has a consensus price target of $72.29, indicating a potential downside of 8.03%. LivaNova has a consensus price target of $64.60, indicating a potential upside of 36.69%. Given LivaNova's higher probable upside, analysts clearly believe LivaNova is more favorable than TransMedics Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TransMedics Group
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86
LivaNova
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50

LivaNova has a net margin of -7.83% compared to TransMedics Group's net margin of -23.76%. LivaNova's return on equity of 10.40% beat TransMedics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
TransMedics Group -23.76% -18.30% -11.84%
LivaNova -7.83% 10.40% 5.54%

In the previous week, TransMedics Group had 4 more articles in the media than LivaNova. MarketBeat recorded 9 mentions for TransMedics Group and 5 mentions for LivaNova. LivaNova's average media sentiment score of 0.96 beat TransMedics Group's score of 0.61 indicating that LivaNova is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TransMedics Group
4 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
LivaNova
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

88.6% of TransMedics Group shares are owned by institutional investors. Comparatively, 98.9% of LivaNova shares are owned by institutional investors. 6.7% of TransMedics Group shares are owned by company insiders. Comparatively, 0.2% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

LivaNova beats TransMedics Group on 10 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TMDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TMDX vs. The Competition

MetricTransMedics GroupElectromedical equipment IndustryMedical SectorNASDAQ Exchange
Market Cap$2.57B$3.43B$4.59B$6.27B
Dividend YieldN/A1.56%2.37%6.38%
P/E Ratio-83.078.2194.7912.16
Price / Sales27.4958.193,431.0788.98
Price / CashN/A15.1391.06107.03
Price / Book13.446.144.715.31
Net Income-$36.23M$86.83M$117.69M$192.96M
7 Day Performance9.26%1.81%2.64%3.85%
1 Month Performance11.25%-1.91%1.97%5.16%
1 Year Performance183.27%21.63%11.38%1.70%

TransMedics Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LIVN
LivaNova
2.417 of 5 stars
$47.05
+1.5%
$64.60
+37.3%
-32.6%$2.53B$1.02B-30.552,900
ITGR
Integer
1.8164 of 5 stars
$83.25
+0.7%
$88.67
+6.5%
+9.8%$2.77B$1.38B41.0110,000Analyst Revision
Positive News
INMD
InMode
2.3573 of 5 stars
$34.56
+1.3%
$45.71
+32.3%
+31.6%$2.83B$474.42M17.19362
CNMD
CONMED
1.7046 of 5 stars
$126.95
+1.1%
$130.40
+2.7%
N/A$3.88B$1.05B-39.064,100
OM
Outset Medical
0.9286 of 5 stars
$22.93
+6.1%
$24.50
+6.8%
+1.3%$1.13B$115.38M-6.50444
BLFS
BioLife Solutions
1.7162 of 5 stars
$24.08
+1.7%
$28.00
+16.3%
+60.2%$1.05B$161.76M-7.06432
MASI
Masimo
2.5853 of 5 stars
$166.18
+0.9%
$188.88
+13.7%
+16.2%$8.77B$2.30B76.236,000
BBIO
BridgeBio Pharma
2.606 of 5 stars
$16.04
+9.9%
$26.63
+66.0%
+105.7%$2.57B$77.65M-5.65576
RVNC
Revance Therapeutics
2.1061 of 5 stars
$30.94
-0.8%
$42.36
+36.9%
+141.0%$2.60B$132.57M-6.71495Analyst Report
BEAM
Beam Therapeutics
1.5966 of 5 stars
$34.33
+1.1%
$67.91
+97.8%
-10.8%$2.62B$60.92M-7.71341

Related Companies and Tools

This page (NASDAQ:TMDX) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -